{"id":13054,"date":"2021-08-05T18:02:57","date_gmt":"2021-08-05T12:32:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=13054"},"modified":"2021-08-31T14:38:07","modified_gmt":"2021-08-31T09:08:07","slug":"recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna","title":{"rendered":"Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0634ac251c6\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0634ac251c6\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna\/#Sanofi_bets_USD_32_Billion_on_mRNA_with_a_deal_to_acquire_Translate_Bio\" >Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna\/#Marinus_hands_over_EU_rights_to_Orion_in_USD_30_Million_upfront_deal_for_anti-seizure_med\" >Marinus hands over EU rights to Orion in USD 30 Million upfront deal for anti-seizure med&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna\/#J_J_Google_back_inflammatory_disease_startup_Mestag_with_USD_45_Million_seed\" >J&amp;J, Google back inflammatory disease startup Mestag with USD 45 Million seed<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna\/#Moderna_secures_FDA_fast_track_designation_for_respiratory_syncytial_virus_vaccine\" >Moderna secures FDA fast track designation for respiratory syncytial virus vaccine<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-sanofi-bets-usd-3-2-billion-on-mrna-with-a-deal-to-acquire-translate-bio\"><span class=\"ez-toc-section\" id=\"Sanofi_bets_USD_32_Billion_on_mRNA_with_a_deal_to_acquire_Translate_Bio\"><\/span><strong>Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi is betting the genetic technology behind the fast development of two highly effective <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>coronavirus <\/strong><\/a>shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acquire a research partner Translate Bio for USD 3.2 billion.&nbsp;<\/p>\n\n\n\n<p>The acquisition is the recent sign that large pharmaceutical companies view messenger RNA, which BioNTech and Moderna utilized to develop the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>COVID-19 vaccines<\/strong><\/a> now cleared for use in dozens of countries, as a crucial drug-making platform.&nbsp;<\/p>\n\n\n\n<p>Pfizer partnered with BioNTech early in the pandemic and zeroed in to develop <a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\"><strong>mRNA vaccines<\/strong><\/a> for other infectious diseases, beginning with influenza. GlaxoSmithKline is working with German mRNA specialist CureVac, while the executive chairman of Novartis recently announced that his company was considering an investment in the technology, too.&nbsp;<\/p>\n\n\n\n<p>For Sanofi, buying Translate Bio follows the latest commitment to spend nearly USD 500 million a year on mRNA vaccine development through a new research unit that the French drugmaker intends to staff with 400 employees in the U.S. and France.&nbsp;<\/p>\n\n\n\n<p>The Lexington, Massachusetts-based biotech is familiar to Sanofi, as the two companies have been partnered since 2018. Last year, they agreed to create an experimental coronavirus vaccine that, after some delay, is now in a Phase 1\/2 clinical trial. Initial results are anticipated by the end of September.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Marinus_hands_over_EU_rights_to_Orion_in_USD_30_Million_upfront_deal_for_anti-seizure_med\"><\/span><strong>Marinus hands over EU rights to Orion in USD 30 Million upfront deal for anti-seizure med&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Marinus Pharmaceuticals has provided the European rights for antiseizure medicine <a href=\"https:\/\/www.delveinsight.com\/report-store\/ganaxolone-emerging-insight-market-forecast\"><strong>ganaxolone<\/strong><\/a><strong> <\/strong>to Orion in exchange for a USD 30 million upfront fee and milestones.<\/p>\n\n\n\n<p>Radnor, Pennsylvania-based Marinus could receive up to USD 115 million later on in reimbursement, development, and commercialization milestone payments as well as royalties on sales. The upfront payment is subject to specific provisions related to some additional preclinical testing that Marinus will require to complete. This work is anticipated to wrap up in the first quarter of 2022.<\/p>\n\n\n\n<p>The commercialization deal confers rights to Orion for ganaxolone in the European economic area, the U.K., and Switzerland for the oral and IV formulations of the therapy for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market\"><strong>treatment of CDKL5 deficiency disorder (CDD)<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/tuberous-sclerosis-complex-market\"><strong>tuberous sclerosis complex<\/strong><\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/refractory-status-epilepticus-rse-market\"><strong>refractory status epilepticus<\/strong><\/a>.<\/p>\n\n\n\n<p>The deal will allow Orion for extensive commercial infrastructure across Europe and forte in rare <a href=\"https:\/\/www.delveinsight.com\/blog\/key-companies-in-neurological-disorders-market\"><strong>neurological disorders<\/strong><\/a>, as per a statement by Marinus.<\/p>\n\n\n\n<p>Marinus will pursue clinical development of the therapy and move it via the regulatory process in Europe. A filing in the region is foreseen by the end of the third quarter.<\/p>\n\n\n\n<p>Orion, meanwhile, will take care of pricing and reimbursement approvals and commercialization in the particular regions. Ganaxolone is set to launch in mid-2022 so long as it secures approval to treat CDD patients.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"J_J_Google_back_inflammatory_disease_startup_Mestag_with_USD_45_Million_seed\"><\/span><strong>J&amp;J, Google back inflammatory disease startup Mestag with USD 45 Million seed<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With a novel fibroblast collaboration already working with Johnson &amp; Johnson&#8217;s Janssen unit, Mestag Therapeutics is further linking arms with the healthcare giant through a USD 45 million seed financing.<\/p>\n\n\n\n<p>The UK-based biotech extended its seed round to include Amsterdam investment firm Forbion alongside Google&#8217;s GV, Northpond Ventures, and founding backers SV Health Investors and J&amp;J Innovation.&nbsp;<\/p>\n\n\n\n<p>In May, Mestag inked a deal with Janssen under which the small biotech would look at fibroblast subpopulations across diseases. Fibroblasts are cells, which develop connective tissue and lead processes such as wound healing.&nbsp;<\/p>\n\n\n\n<p>Janssen has the option for an exclusive license to develop and commercialize therapies directed against up to two targets through the deal. No financial terms were revealed.&nbsp;<\/p>\n\n\n\n<p>A year-old Mestag has the funds to build a pipeline of antibodies and bring its single-cell approach toward the clinic.&nbsp;<\/p>\n\n\n\n<p>Mestag is led by CEO Susan Hill, Ph.D., who was previously a chief business officer of <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-for-ocular-rare-disease-market\"><strong>retinal gene therapy<\/strong><\/a> biotech Gyroscope Therapeutics and CEO of Orbit Biomedical before that.<\/p>\n\n\n\n<p>Fibroblasts are part of the platform fueling <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-and-cell-therapies-targeting-cns-disorders-market\"><strong>cell-based gene therapy<\/strong><\/a> biotech Castle Creek.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Moderna_secures_FDA_fast_track_designation_for_respiratory_syncytial_virus_vaccine\"><\/span><strong>Moderna secures FDA fast track designation for respiratory syncytial virus vaccine<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-pipeline-insight\"><strong>COVID-19 vaccine<\/strong><\/a> pioneer Moderna aims to develop one of the first <a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\"><strong>mRNA-based vaccines<\/strong><\/a> against the <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\"><strong>respiratory syncytial virus (RSV)<\/strong><\/a>. Now, the FDA has granted fast track designation for mRNA-1345, an experimental single-dose mRNA RSV vaccine in adults 60 and older.<\/p>\n\n\n\n<p>Pfizer, Johnson &amp; Johnson, GlaxoSmithKline, Novavax, and Bavarian Nordic are also developing RSV vaccines. None of those, however, use an mRNA platform.<\/p>\n\n\n\n<p>According to the CDC, RSV generally causes mild cold-like symptoms but can lead to serious illness in infants and the elderly. In infants, RSV often leads to pneumonia and another type of respiratory tract infection known as bronchiolitis.<\/p>\n\n\n\n<p>Moderna hopes to eventually secure regulatory approval to utilize the mRNA-1345 vaccine to protect the most vulnerable populations \u2013 young children and older adults, as stated by St\u00e9phane Bancel, CEO of Moderna. The company currently has a Phase 1 study involving mRNA-1345 assessing its performance in younger adults, older adults, and children. The company presently has 11 vaccines for infectious diseases in human clinical trials. The pandemic has increased Moderna\u2019s capacity to develop drugs independently and sharpened its focus on infectious diseases.<br>Moderna has secured fast track designation for other investigational therapies, including its COVID-19 vaccine, <a href=\"https:\/\/www.delveinsight.com\/report-store\/zika-virus-infection-pipeline-insight\"><strong>Zika vaccine<\/strong><\/a> candidate (mRNA-1893), <a href=\"https:\/\/www.delveinsight.com\/report-store\/methylmalonic-acidemia-market\"><strong>methylmalonic acidemia (MMA)<\/strong><\/a> (mRNA-3704), and <a href=\"https:\/\/www.delveinsight.com\/report-store\/propionic-acidemia-market\"><strong>propionic acidemia<\/strong><\/a> (mRNA-3927) programs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acquire [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":13057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[349,420,639],"industry":[17225],"therapeutic_areas":[17229,17243],"class_list":["post-13054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-latest-pharma-news","tag-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi bets $3.2B on mRNA | Marinus&#039;s $30M deal | Mestag bags $45M<\/title>\n<meta name=\"description\" content=\"Mestag with $45M seed; Moderna secures fast track designation; Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi bets $3.2B on mRNA | Marinus&#039;s $30M deal | Mestag bags $45M\" \/>\n<meta property=\"og:description\" content=\"Mestag with $45M seed; Moderna secures fast track designation; Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-05T12:32:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-31T09:08:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/05183725\/recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi bets $3.2B on mRNA | Marinus's $30M deal | Mestag bags $45M","description":"Mestag with $45M seed; Moderna secures fast track designation; Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna","og_locale":"en_US","og_type":"article","og_title":"Sanofi bets $3.2B on mRNA | Marinus's $30M deal | Mestag bags $45M","og_description":"Mestag with $45M seed; Moderna secures fast track designation; Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion....","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-08-05T12:32:57+00:00","article_modified_time":"2021-08-31T09:08:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/05183725\/recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna","name":"Sanofi bets $3.2B on mRNA | Marinus's $30M deal | Mestag bags $45M","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/05183725\/recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna.png","datePublished":"2021-08-05T12:32:57+00:00","dateModified":"2021-08-31T09:08:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Mestag with $45M seed; Moderna secures fast track designation; Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-sanofi-marinus-orion-mestag-moderna#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/05183725\/recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/05183725\/recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna.png","width":772,"height":482,"caption":"recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/05183725\/recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 5, 2021","modified":"Updated on Aug 31, 2021"},"absolute_dates_time":{"created":"Posted on Aug 5, 2021 6:02 pm","modified":"Updated on Aug 31, 2021 2:38 pm"},"featured_img_caption":"recent-pharma-news-and-updates-for-sanofi-marinus-orion-mestag-moderna","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=13054"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13054\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/13057"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=13054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=13054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=13054"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=13054"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=13054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}